<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><description>It takes nothing to join the crowd, but it takes everything to stand alone</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 20 May 2021 07:25:37 +0800</pubDate><image><url>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</url><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>关于阿达木单抗生物类似药质量相似性评价要点的初步探讨</title><link>https://mp.weixin.qq.com/s/Jlctvcw42GzwdFUim_L1jQ</link><description></description><content:encoded><![CDATA[关于阿达木单抗生物类似药质量相似性评价要点的初步探讨]]></content:encoded><pubDate>Wed, 19 May 2021 20:36:40 +0800</pubDate></item><item><title>CDE答疑：生物制品上市后变更专题</title><link>https://mp.weixin.qq.com/s/MWe28VmOle6pm1TYq02oSQ</link><description></description><content:encoded><![CDATA[CDE答疑：生物制品上市后变更专题]]></content:encoded><pubDate>Wed, 19 May 2021 20:36:40 +0800</pubDate></item><item><title>无菌生产工艺控制的五点关注</title><link>https://mp.weixin.qq.com/s/MwYzlLszN5hD2RgSL28Y5Q</link><description></description><content:encoded><![CDATA[无菌生产工艺控制的五点关注]]></content:encoded><pubDate>Wed, 19 May 2021 20:36:40 +0800</pubDate></item><item><title>复习——生物制品上市申请药学申报资料常见问题和审评关注要点分析</title><link>https://mp.weixin.qq.com/s/8ziv-3h7MYQNfs1D0klE0g</link><description></description><content:encoded><![CDATA[复习——生物制品上市申请药学申报资料常见问题和审评关注要点分析]]></content:encoded><pubDate>Tue, 18 May 2021 20:34:37 +0800</pubDate></item><item><title>MAH制度红利持续释放，引燃研发创新项目交易之火</title><link>https://mp.weixin.qq.com/s/vqkq0AiiSFlvj1n1r1GIMg</link><description></description><content:encoded><![CDATA[MAH制度红利持续释放，引燃研发创新项目交易之火]]></content:encoded><pubDate>Tue, 18 May 2021 20:34:37 +0800</pubDate></item><item><title>CAR-T在实体瘤的治疗中最大的阻碍之一：肿瘤微环境</title><link>https://mp.weixin.qq.com/s/z-v-3XmLu_muFKfiU_rjGQ</link><description></description><content:encoded><![CDATA[CAR-T在实体瘤的治疗中最大的阻碍之一：肿瘤微环境]]></content:encoded><pubDate>Tue, 18 May 2021 20:34:37 +0800</pubDate></item><item><title>学习笔记《溶瘤病毒类药物临床试验设计指导原则（试行）》</title><link>https://mp.weixin.qq.com/s/ugyt5B5STA3fp3HbkFfnaw</link><description></description><content:encoded><![CDATA[学习笔记《溶瘤病毒类药物临床试验设计指导原则（试行）》]]></content:encoded><pubDate>Tue, 18 May 2021 20:34:37 +0800</pubDate></item><item><title>CDE-CTD共性问题汇总及解答</title><link>https://mp.weixin.qq.com/s/WjMfPd0bpujLp98eGqTG1Q</link><description></description><content:encoded><![CDATA[CDE-CTD共性问题汇总及解答]]></content:encoded><pubDate>Mon, 17 May 2021 19:41:59 +0800</pubDate></item><item><title>NGM Biopharma技术全梳理</title><link>https://mp.weixin.qq.com/s/MfQQ22N8R7DvBKD5IWY_ag</link><description></description><content:encoded><![CDATA[NGM Biopharma技术全梳理]]></content:encoded><pubDate>Mon, 17 May 2021 19:41:59 +0800</pubDate></item><item><title>一图读懂：红细胞 VS 白细胞</title><link>https://mp.weixin.qq.com/s/ynfj2RbjmNi10g2J15_BIg</link><description></description><content:encoded><![CDATA[一图读懂：红细胞 VS 白细胞]]></content:encoded><pubDate>Mon, 17 May 2021 19:41:59 +0800</pubDate></item><item><title>抗病毒抗体类生物制药的最新进展</title><link>https://mp.weixin.qq.com/s/IM0GlwRz6UVMyj8yHZIA9A</link><description></description><content:encoded><![CDATA[抗病毒抗体类生物制药的最新进展]]></content:encoded><pubDate>Mon, 17 May 2021 19:41:59 +0800</pubDate></item><item><title>严重副作用不同疾病的对应手册（面向患者·公众）（62）-运动障碍</title><link>https://mp.weixin.qq.com/s/wGbomL-JNxERjGMemh3cHg</link><description></description><content:encoded><![CDATA[严重副作用不同疾病的对应手册（面向患者·公众）（62）-运动障碍]]></content:encoded><pubDate>Sun, 16 May 2021 20:43:45 +0800</pubDate></item><item><title>新型冠状病毒重组疫苗早期研发药学关注要点</title><link>https://mp.weixin.qq.com/s/HujhXejiK1JgtddEZFBFyQ</link><description></description><content:encoded><![CDATA[新型冠状病毒重组疫苗早期研发药学关注要点]]></content:encoded><pubDate>Sun, 16 May 2021 20:43:45 +0800</pubDate></item><item><title>预防性mRNA 疫苗的研究进展</title><link>https://mp.weixin.qq.com/s/VkMnVO07ED6JzFmsQxqMXA</link><description></description><content:encoded><![CDATA[预防性mRNA 疫苗的研究进展]]></content:encoded><pubDate>Sun, 16 May 2021 20:43:45 +0800</pubDate></item><item><title>国内首款 Trop-2 ADC 报上市，医保谈判药品“双通道”来了，荣昌生物拟赴科创板上市</title><link>https://mp.weixin.qq.com/s/RsTJc3zoe9F9abevTW84SA</link><description></description><content:encoded><![CDATA[国内首款 Trop-2 ADC 报上市，医保谈判药品“双通道”来了，荣昌生物拟赴科创板上市]]></content:encoded><pubDate>Sat, 15 May 2021 21:06:44 +0800</pubDate></item><item><title>药品评审中心招聘51名编外人员！</title><link>https://mp.weixin.qq.com/s/1i-W1uCPft8G0Kasm0EJOQ</link><description></description><content:encoded><![CDATA[药品评审中心招聘51名编外人员！]]></content:encoded><pubDate>Sat, 15 May 2021 21:06:44 +0800</pubDate></item><item><title>国家卫健委刚刚发布：新冠病毒样本采集和检测技术指南</title><link>https://mp.weixin.qq.com/s/InAflw_CudWJbshb-Ytt-w</link><description></description><content:encoded><![CDATA[国家卫健委刚刚发布：新冠病毒样本采集和检测技术指南]]></content:encoded><pubDate>Sat, 15 May 2021 21:06:44 +0800</pubDate></item><item><title>创新药及仿制药杂质限度确定方法</title><link>https://mp.weixin.qq.com/s/nzcP2krTIjLIv5-NwiWV2A</link><description></description><content:encoded><![CDATA[创新药及仿制药杂质限度确定方法]]></content:encoded><pubDate>Sat, 15 May 2021 21:06:44 +0800</pubDate></item><item><title>早期胃癌筛查标准流程（图文版）</title><link>https://mp.weixin.qq.com/s/lnzs2bIBD5-SACj8hdouAg</link><description></description><content:encoded><![CDATA[早期胃癌筛查标准流程（图文版）]]></content:encoded><pubDate>Fri, 14 May 2021 19:34:56 +0800</pubDate></item><item><title>《药物警戒质量管理规范》花脸稿来了</title><link>https://mp.weixin.qq.com/s/NNTTUe_sbxlD2d0p72TiAg</link><description></description><content:encoded><![CDATA[《药物警戒质量管理规范》花脸稿来了]]></content:encoded><pubDate>Fri, 14 May 2021 19:34:56 +0800</pubDate></item></channel></rss>